Jan Hellemans

Quintiles, Inc. provides therapeutic services. It offers medical services, information and partnering solutions to the pharmaceutical, biotechnology and healthcare industries. The company was founded in 1982 and is headquartered in San Francisco, CA.

Tecan Genomics, Inc. provides genomics sample preparation solutions. It offers solutions which make biological samples accessible for genomic analysis. The firm has commercialized numerous proprietary DNA and RNA sample preparation products for use in research and diagnostic applications. The company was founded by Jan D'Alvise, James W. Larrick and Nurith Kurn in 2000 and is headquartered in San Carlos, CA.

Pacira Cryotech, Inc. develops novel technologies for treatment of peripheral nerves. Its iovera treatment harnesses the power of cold with the Focused Cold Therapy delivery system and delivers immediate results for both therapeutic and aesthetic applications. The firm’s iovera treatment does not use toxins, chemicals, or pharmaceuticals to achieve results and leaves nothing behind in the body. The company was founded by Lisa Elkins in 2005 and is headquartered in Fremont, CA.

Ion Torrent Systems, Inc. develops semiconductor chips for DNA sequencing systems. The company was founded in 2007 and is headquartered in Guilford, CT.

Part of QIAGEN NV, Rapigene, Inc. is a company that provides gene therapy research services. The company is based in Bothell, WA. Rapigene was acquired by QIAGEN NV from Celltech Group Plc on January 10, 2000 for $11.95 million.

MyCartis NV develops technologies for healthcare personalization needs. It offers Evalution, a multiplex analysis platform to develop protein and nucleic-acid based clinical biomarkers. The company provides disruptive solutions in the fields of clinical and translational research for various applications in the detection of proteins and nucleic acids, such as sandwich immunoassays, antibody assays, genotyping assays, and mutation analysis assays to customers and partners. It offers products for various disease areas, including cell signalling, cardiovascular, oncology, and preeclampsia. The company was founded by Koen Kas in August 2004 and is headquartered in Ghent, Belgium.

Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium.

UGent TechTransfer is a venture capital firm, a subsidiary of Ghent University founded in 1999. UGent TechTransfer is headquartered in Zwijnaarde, Belgium.

Trinean NV develops and produces nanoliter spectrophotometers and consumables. Its products include DropSense96, Xpose, and spectral content profiling. The firm covers both microfluidic structures and multi-channel spectrometry for microliter sample handling. The company was founded by Ronny Baeckstaele and Kris Naessens in 2006 and is headquartered in Gentbrugge, Belgium.

Celltech Ltd. provides research and development on natural science and engineering. The company was founded in 1999 and is headquartered in Slough, GB.

Q-Biologicals NV operates as a bio pharma contract development and manufacturing organization. It provides process development and bio manufacturing services to customers in the biopharmaceutical industry. The company was founded in 2011 and is headquartered in Ghent, Belgium.

QBIC Venture Partners BVBA (QBIC Venture Partners) is a venture capital firm founded in 2012 by Marc Zabeau. The firm is headquartered in Belgium.

Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium.

Evonetix Ltd. is a biotechnology company. The firm offers pharmaceuticals and drug discovery, industrial biotech and renewables, materials science, agriculture, digital data storage, and food and beverages. The company was founded by Hermann Maria Hauser and Joseph Brennan in 2015 and is headquartered in Little Chesterford, the United Kingdom.

Longas Technologies Pty Ltd. is engaged in developing next generation sequencing (NGS) technologies. The company was founded by Ian Charles, Aaron Darling, and Catherine Burke in 2015 and is headquartered in Sydney, Australia.

Calypso Biotech BV operates as immunotherapy biotech company. It develops monoclonal antibodies for the treatment of immune pathologies with large unmet medical needs. The company was founded by Alain Vicari and Yolande Chvatchko in 2013 and is headquartered in Amsterdam, the Netherlands.

Dualyx NV is a biotech company based in Ghent, Belgium that focuses on developing novel Treg-based therapies for patients with difficult-to-treat autoimmune diseases. The CEO of the company is Wouter Verhoeven, and it is located in Zwijnaarde, Belgium. Dualyx has developed a pipeline of highly promising immune modulating programs, including DT-001, an antibody agonist program targeting the TNF receptor 2 (TNFR2), which is currently in IND-enabling studies. The Belgian company aims to create next-generation biologic drugs for autoimmunity therapies with novel mechanisms of action, lower toxicity, and improved patient outcomes than traditional therapeutics. The company was founded in 2020 by Luc van Rompaey in collaboration with Wurzburg University, Argenx, VIB, Ghent University, and KU Leuven.

Strebo Services Srl operates rest and care homes. The private company is based in La Louvière, Belgium. The Belgian company was founded in 2008. The CEO is Stéphane Mercier.

THERAtRAME SA is a drug discovery start-up company based in Liege, Belgium. The Belgian company aims to become a leader in the development and positioning of novel cancer therapies by exploring new target areas to develop innovative cancer therapies. THERAtRAME's discovery platform integrates unique sets of technologies to discover, develop, and position new drugs to beat reluctant cancers. The company exploits the latest scientific discoveries highlighting the unexpected importance of trna epitranscriptomics dynamics in cancer. THERAtRAME is looking for a drug discovery assay developer leader to join their team. The company was founded by Francesca Rapino, Pierre Close, and has a team of experienced professionals with backgrounds in life sciences, medico-marketing, and biotech venture creations.

The Charcot-Marie-Tooth Association operates as a non-profit organization. The private company is based in Glenolden, PA. Suzanne Louise Bruhn has been the CEO of the company since 2023.